Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | TSHR | P16473 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20965335 | 0.91 | L3MBTL1 (0.66) | SMN1; SMN2KMT2ATSHRMEN1L3MBTL1 | |
| SCHEMBL20964625 | 0.90 | L3MBTL1 (0.66) | SMN1; SMN2KMT2ATSHRMEN1L3MBTL1 | |
| SCHEMBL20965411 | 0.90 | L3MBTL1 (0.66) | SMN1; SMN2KMT2ATSHRMEN1L3MBTL1 | |
| SCHEMBL20965449 | 0.89 | L3MBTL1 (0.67) | SMN1; SMN2KMT2ATSHRMEN1L3MBTL1 | |
| SCHEMBL20965433 | 0.88 | L3MBTL1 (0.66) | SMN1; SMN2KMT2ATSHRMEN1L3MBTL1 | |
| SCHEMBL20964721 | 0.86 | L3MBTL1 (0.77) | SMN1; SMN2KMT2ATSHRMEN1L3MBTL1 | |
| SCHEMBL20964644 | 0.85 | SMN1; SMN2 (0.71) | SMN1; SMN2KMT2ATSHRMEN1L3MBTL1 | |
| SCHEMBL20964608 | 0.85 | L3MBTL1 (0.61) | SMN1; SMN2KMT2ATSHRMEN1L3MBTL1 | |
| SCHEMBL20964544 | 0.85 | L3MBTL1 (0.68) | SMN1; SMN2KMT2ATSHRL3MBTL1NPC1 | |
| SCHEMBL20964656 | 0.84 | L3MBTL1 (0.73) | SMN1; SMN2TSHRL3MBTL1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190127361-A1 | Therapeutic Compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3471729-A1 | THERAPEUTIC COMPOUNDS | Rutgers, the State University of New Jersey (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017222930-A1 | THERAPEUTIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127361-A1 | Therapeutic Compounds | SDHA, SLC10A1, SERPINC1 | SMN1; SMN2 263/4885KMT2A 4728/4885TSHR 3423/4885 |
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | SERPINC1, F12, RPL35 | SMN1; SMN2 2477/4885KMT2A 3241/4885TSHR 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.